BioMarin Sustainability Profile
BioMarin Pharmaceutical Inc., headquartered in the United States, is a leading biotechnology company specialising in innovative therapies for rare genetic diseases. Founded in 1997, BioMarin has established itself as a pioneer in the industry, focusing on the development of enzyme replacement therapies and gene therapies that address unmet medical needs. With a strong presence in North America, Europe, and Asia, BioMarin's core products include treatments for conditions such as phenylketonuria (PKU) and mucopolysaccharidosis (MPS). The company is renowned for its commitment to research and development, which has led to several groundbreaking therapies that significantly improve patient outcomes. BioMarin's dedication to rare disease treatment has positioned it as a market leader, earning recognition for its innovative approach and impactful contributions to the biotechnology sector.
DitchCarbon Score
How does BioMarin's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
BioMarin's score of 25 is lower than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
BioMarin's reported carbon emissions
BioMarin Pharmaceutical Inc., headquartered in the US, currently does not provide specific carbon emissions data for the most recent year, as indicated by the absence of reported figures. Consequently, there are no details available regarding their Scope 1, 2, or 3 emissions. In terms of climate commitments, BioMarin has not outlined any specific reduction targets or initiatives in the provided data. This lack of information suggests that the company may still be in the early stages of developing a comprehensive climate strategy or reporting framework. As a member of the pharmaceutical industry, BioMarin is part of a sector increasingly focused on sustainability and carbon reduction. However, without specific emissions data or defined targets, it is challenging to assess their current impact or future commitments in relation to climate change.
How Carbon Intensive is BioMarin's Industry?
How Carbon Intensive is BioMarin's Location?
BioMarin's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
BioMarin has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
